Category Archives: Press Releases

May 22,2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) reported its financial results for the three months ended March 31, 2018. All figures are reported in CDN dollars ($), unless otherwise indicated. Delivra’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

Operational Highlights for the First Quarter:

  • Developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of cannabis, opioids, and similar molecules, for a safer, more targeted and consistent delivery to patients afflicted with chronic pain and anxiety;
  • Advanced selected applications closer to the status of a “product” ready for licensing, to present to potential pharma partners a very specific and highly evolved product licensing proposal(s), to expedite licensing opportunities;
  • Concluded a distribution agreement with NKS Health Ltd. (“NKS”), granting NKS the right to compound, distribute, promote, market and sell new unique pharmaceutical compounded product formulas for diabetes and other pain related issues, developed by Delivra;
  • The Company hired a national, coast-to-coast Agency with strategic in-store representation at the beginning of the year. This new Agency will ensure that across all retail locations in Canada, the LivRelief product offerings are: Maximized at all locations, all tactical marketing initiatives are being followed, and to educate and expand the knowledge of pharmacists on the unique LivRelief product offerings, further enhancing the profile of LivRelief as the #1 recommended topical cream brand of choice. During this transition to the new Agency, there was a temporary pause during the quarter on sales and other initiatives, while the new Agency was integrated into our programs and we began the introductions to our key retail partners across the country. We believe this new strategic relationship and expanded reach will enhance the awareness of our unique product offerings and assist in further driving sales from coast-to-coast;
  • Created a new position, hiring a Director of Sales in April 2018 to oversee the LivRelief over-the-counter portfolio; and
  • Subsequent to the quarter end, the Company strengthened its balance sheet, completing a non-brokered private placement through the issuance of 3,561,423 units for gross proceeds of $1,246,498. Each unit comprised one common share and one common share purchase warrant.
May 3, 2018 – Toronto, Ontario – Delivra Corp. (“Delivra”, or “the Company”) today announced the publication of their analytical evaluation of a variety of third-party over-the-counter hemp consumer products for tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) content to further develop its internal expertise and evaluate the consumer landscape.

April 26, 2018 – Toronto, Ontario – Delivra Corp. (“Delivra”, or “the Company”) today announced that its R&D, pre-clinical and clinical teams have successfully developed and tested line-extension products using its precision topical delivery system platform, DelivraTM. These consumer product initiatives include cannabis-related products at both the over-the-counter (“OTC”) and prescription levels. With the assistance and support of Emergence, Canada’s virtual incubator that supports the growth of innovative bioscience and food sector ventures, Delivra has developed its strategy and executed on ready to use products for OTC line extensions that will compliment its already existing successful LivRelief products, and is ready for the upcoming legalization of cannabis with its vast array of cannabis-related products for third party distributors for different disease indications.

April 18, 2018 – Toronto, Ontario – Delivra Corp. (“Delivra”, or “the Company”) today announced the publication of positive data from a pre-clinical study demonstrating the safety and greater bioavailability of transdermal berberine and dihydroberberine (DHB) for the prevention and treatment of cardiovascular disease related to high cholesterol and triglyceride levels. These results were published in the respected peer-reviewed scientific journal, PLOS ONE, under the title, “Comparative Pharmacokinetics and Safety Assessment of Transdermal Berberine and Dihydroberberine”. The article may be found at the following link: https://doi.org/10.1371/journal.pone.0194979.

April 10, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) reported its financial results for the three and twelve months ended December 31, 2017. All figures are reported in CDN dollars ($), unless otherwise indicated. Delivra’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

Financial and Operational Highlights for Fiscal 2017:

  • Record sales of $4,513,253, representing 20% sales growth over 2016;
  • Streamlined operations, reducing operating expenditures by $2,952,470 over 2016, while achieving record sales;
  • Significantly reduced cash burn from operating activities by an average of $210,450 per month versus prior year;
  • Development pipeline continues to be very robust, including products targeted towards conditions which represent significant market opportunities, such as osteoarthritis, sleep, psoriasis, migraines, cardiovascular disease, and circulation;
  • Completed a licensing agreement with ARA-Avanti RX Analytics Inc., recently purchased by Aphria Inc., for medicinal products for medical and pain-related development using hemp;
  • Subsequent to the year end:
    • concluded an agreement with NKS Health to promote the Company’s cream-based pharmaceutical therapeutics for pain, anxiety and diabetic foot ulcers; and
    • completed non-brokered private placement for gross proceeds of $1,246,498.
TORONTO, ONTARIO – April 5, 2018 – Delivra Corp. (TSXV: DVA) (the “Company” or “Delivra”) has completed a non-brokered private placement through the issuance of 3,561,423 units (“Units”, as defined below) of the Company for gross proceeds of $1,246,498.20 (the “Offering”).

Each Unit consists of one common share of the Company (a “Share”) and one share purchase warrant (a “Warrant”). Each whole Warrant will entitle the holder to purchase one Share at a price of $0.50 per Share for 24 months from the date of closing, subject to the option of the Company, in the event that the closing price of Shares on the TSX Venture Exchange (the “TSXV”) equals or exceeds $0.90 per Share for 10 consecutive days, to accelerate the expiry of the Warrants to 30 days after acceleration notice (the “Acceleration Option”).

February 1, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) announced today that it has signed a non-exclusive distribution agreement with NKS Health Ltd. (“NKS”), granting NKS the right to compound, distribute, promote, market and sell new unique pharmaceutical compounded product formulas developed by Delivra. The goal of the agreement is to build a partnership to both grow awareness and increase volume of sales for the Company’s pharmaceutical pipeline.

NKS will promote Delivra’s cream-base therapeutics to physicians, hospitals and clinics in Canada through its network. Delivra has developed a suite of compounded products for pain, anxiety and diabetic foot ulcers. These products include: cannabis-like molecules (nabilone), opioids (buprenorphine), celebrexTM, neuropathic molecules like gabapentin for nerve related pain and the antibiotic doxycycline for diabetic foot ulcers. The agreement is effective until December 2019.

January 25, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) announced today the Company has signed a joint venture agreement using Delivra’s revolutionary, proprietary topical therapeutic platform (DelivraTM). The DelivraTM topical base cream can accommodate hundreds of molecules that can be used for the human and animal health sectors.

“This anxiety product combines safe, natural products, with our transdermal delivery system that makes administration easy by pet owners; offering a unique and particularly powerful advantage in the current animal anxiety treatment market. Given the companion animal market is estimated to exceed $65 billion in sales in the United States alone with medical product sales representing approximately 20% of total market sales, we see an enormous opportunity for revenue generation through leveraging our proprietary transdermal delivery system in the animal health market,” said Dr. Joseph Gabriele, CEO of Delivra.

January 16, 2018 – Toronto, Ontario – Delivra Corp. (TSXV: DVA – “Delivra” or the “Company”) announced today the Company has developed a revolutionary, proprietary topical cream base therapeutic, DelivraTMN, for molecules of Cannabis, Cannabis-like and opioids, for a safer, more targeted and consistent delivery to patients afflicted with chronic pain and anxiety.

“Our goal is to develop innovative products using our proprietary topical delivery platform (DelivraTM) to meet significant unmet medical needs and improve quality of life. With our proven patent-pending technology and formulation expertise, we have created medical grade products that have shown significant efficacy and predictable outcomes to patients,” said Dr. Joseph Gabriele, CEO of Delivra. “With the capability to deliver products on the market immediately that provide superior efficacy with minimum side effects that are commercial-ready, Delivra will capitalize on the significant growth opportunities ahead and advance innovative and alternative therapeutics to broaden the Company’s product offerings.”